An Intermediate Size Expanded Access Protocol of Elamipretide
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor to learn more about this program. The treating physician must contact StealthBiotherapeutics using the Expanded Access Program Contacts provided. Elamipretide will only be made available after careful review of an individual request submitted by the treating physician. The initiation and conduct of the treatment with elamipretide for an individual patient, and compliance with this treatment guideline, will be under the full and sole responsibility of the treating physician.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
1 Year to 80 Years (Child, Adult, Older Adult)
Sexes Eligible for Study:
Key Inclusion Criteria:
≥1 year and ≤ 80 years of age
Patients with genetically confirmed rare primary mitochondrial diseases
observed cardiomyopathy, renal impairment, neuropathic, or ophthalmic manifestation
where such disease is serious or life-threatening and no comparable or satisfactory alternative therapy options available.
Patients without genetic confirmation of a rare disease with known mitochondrial dysfunction but do exhibit serious or life-threatening clinical manifestations of mitochondrial dysfunction.
Is self-able or has caregiver willing and able to administer SC injection.
Would potentially benefit from treatment with elamipretide and cannot be treated satisfactorily with any approved medicinal product in the opinion of the treating physician.
Key Exclusion Criteria:
Known hypersensitivity to elamipretide or any excipients.
Women who are pregnant, are planning on becoming pregnant, or are breast-feeding.
Patients receiving any other investigational agent within 30 days of dosing.
Any active, serious psychiatric, medical, or other conditions/situations which, in the treating physician's opinion, could compromise the patient's safety.